Calendario›PBYI›Neratinib

Neratinib

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Ensayo de PUMA BIOTECHNOLOGY, INC. en Cancer de mama.

Más ensayos de: Cáncer de mama.

Fase

Fase 1/2

Estado

Completado

Participantes

105

previstos

Centros

37

Fin del objetivo primario

nov 2010

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en dic 2008.

Qué mide

Number of Participants With Dose Limiting Toxicities (From first dose date to day 21) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a world wide phase 1/2, open-label, study of neratinib in combination with capecitabine, conducted in 2 parts. In Part 1, 3 to 9 subjects with solid tumors will be enrolled in each dose group of the combination of neratinib and capecitabine. Each subject will participate in only 1 dose group. Additional subjects may be included at any dose level to further assess the safety and tolerability at that dose level. In Part 2, up to 60 subjects with erbB-2 positive metastatic breast cancer will receive treatment with the combination of neratinib and capecitabine at the maximum tolerated dose level, as determined in Part 1. In addition 20 subjects with prior lapatinib exposure will be enrolled in Part 2. Depending on the safety and activity profile observed during the dose escalation phase, the dose selected for Part 2 may be adjusted, if appropriate. In case one test article of the combination is discontinued due to intolerance the other test article can be administered alone. The primary objectives of Part 1 are to assess the safety and tolerability, and to define the maximum tolerated dose (MTD) of neratinib in combination with capecitabine in subjects with advanced solid tumors. The primary objective of Part 2 of this study is to confirm the MTD determined in Part 1. The secondary objective of Part 1 is to collect information on preliminary anti-tumor activity of the combination of neratinib and capecitabine. Secondary objectives for Part 2 are to collect pharmacokinetic information and to obtain additional efficacy data, such as Objective Response Rate, for subjects with erbB-2 positive breast cancer treated at the MTD of neratinib + capecitabine.

Más ensayos de PBYI

Todos los de PBYI, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00741260), actualizada en ago 2018.